The polymyxin and lipopeptide classes of antibiotics are membrane-targeting drugs of last
resort used to treat infections caused by multi-drug-resistant pathogens. Despite similar …

Staphylococcus aureus, a ubiquitous pathogen, is the most common bacteria involved in
purulent acute bacterial skin and skin structure infections (ABSSSI) 1. Over the years …

Background High-dose daptomycin is increasingly used in patients with bone and joint
infection (BJI). This raises concerns about a higher risk of adverse events (AEs), including …

This systematic review and meta-analysis compares the efficacy of daptomycin and
vancomycin in adult patients with bacteremia by methicillin-resistant Staphylococcus aureus …

Background There is a growing concern about the association between the combined use of
daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events …

Therapeutic drug monitoring (TDM) could optimise daptomycin use. However, no validated
serum target levels have been established. This prospective study at a tertiary centre …

Objectives The CLSI recommended high-dose daptomycin (8–12 mg/kg) for treating
Enterococcus faecium bloodstream infections (BSI). The current study was designed to …

Methicillin-resistant Staphylococcus aureus (MRSA) causes biofilm-related medical device
infections. Phage-antibiotic combinations offer potential therapy due to proven in vitro …

Introduction: Acute bacterial skin and skin-structure infections (ABSSSI) may develop in both
in-patients and out-patients, possibly with a severe clinical presentation. Since most phase 3 …

Background In this study, we investigated the risk factors for daptomycin-associated creatine
phosphokinase (CPK) elevation and established a risk score for CPK elevation. Methods …